In MJD, VPA was reported to alleviate neurodegeneration in a Drosophila model of the disease [19] and to attenuate mutant ATXN3-induced cell toxicity in a human neuronal cell model [20]. This evidence concerns the gene ATXN3 and Machado-Joseph disease.